A5036373330- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Cancer Mechanisms and Therapy
- RNA modifications and cancer
- Protein Tyrosine Phosphatases
- Cancer-related Molecular Pathways
- Ubiquitin and proteasome pathways
- RNA Research and Splicing
- CRISPR and Genetic Engineering
- Estrogen and related hormone effects
- DNA Repair Mechanisms
- Galectins and Cancer Biology
- Glycosylation and Glycoproteins Research
- Chronic Lymphocytic Leukemia Research
- Genetics, Aging, and Longevity in Model Organisms
- Cytokine Signaling Pathways and Interactions
- Biochemical and Molecular Research
- ATP Synthase and ATPases Research
- Fungal and yeast genetics research
- Epigenetics and DNA Methylation
Universidade de São Paulo
2018-2024
Hôpital Maisonneuve-Rosemont
2022-2023
Université de Montréal
2022
Discovery Institute
2017
Institute of Chemistry
2017
Abstract Background Information The dual‐specificity phosphatase 3 (DUSP3) regulates cell cycle progression, proliferation, senescence, and DNA repair pathways under genotoxic stress. This interacts with HNRNPC protein suggesting an involvement in the regulation of HNRNPC‐ribonucleoprotein complex stability. In this work, we investigate impact DUSP3 depletion on functions aiming to suggest new roles for enzyme. Results knockdown results tyrosine hyperphosphorylation state increasing its RNA...
The dual-specificity phosphatase 3 (DUSP3), an atypical protein tyrosine (PTP), regulates cell cycle checkpoints and DNA repair pathways under conditions of genotoxic stress. DUSP3 interacts with the nucleophosmin (NPM) in nucleus after UV-radiation, implying a potential role for this interaction mechanisms genomic stability. Here, we show high-affinity binding between DUSP3-NPM NPM phosphorylation UV stress, which is increased knockdown cells. Specific antibodies designed to four...
Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature their use single agents melanoma has shown limited clinical benefit. Herein, we discovered that treatment tumor cells with palbociclib induces phosphorylation mRNA translation initiation factor eIF4E. When phosphorylated, eIF4E specifically engenders mRNAs code proteins involved cell survival. We...
<p>Supplementary Figure 1</p>
<p>List of differentially expressed proteins annotated by cluster with pathway analysis in BLM cells</p>
<div>Abstract<p>Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature their use single agents melanoma has shown limited clinical benefit. Herein, we discovered that treatment tumor cells with palbociclib induces phosphorylation mRNA translation initiation factor eIF4E. When phosphorylated, eIF4E specifically engenders mRNAs code proteins...
<p>Supplementary Figure 3</p>
<p>Supplementary methods and Tables 1, 2, 3, 4, 6</p>
<p>Supplementary methods and Tables 1, 2, 3, 4, 6</p>
<div>Abstract<p>Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature their use single agents melanoma has shown limited clinical benefit. Herein, we discovered that treatment tumor cells with palbociclib induces phosphorylation mRNA translation initiation factor eIF4E. When phosphorylated, eIF4E specifically engenders mRNAs code proteins...
<p>List of differentially expressed proteins annotated by cluster with pathway analysis in BLM cells</p>
<p>Supplementary Figure 1</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 2</p>
<p>Supplementary Figure 3</p>